These findings suggest that targeting the ITGB1-PI3K/AKT-G6PD axis may be a suitable strategy to counteract the influence of ECM stiffness on sorafenib resistance in HCC. This evidence concerns the gene ITGB1 and hepatocellular carcinoma.